Patents by Inventor Michael D. Kaplan
Michael D. Kaplan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12365728Abstract: Provided herein are binding polypeptides that specifically bind DLL3. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific contracts and chimeric antigen receptors, that bind DLL3. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided DLL3 binding polypeptides for treating diseases and conditions, such as cancer.Type: GrantFiled: October 9, 2019Date of Patent: July 22, 2025Assignee: Inhibrx Biosciences, Inc.Inventors: Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, Rajay A. Pandit, Angelica N. Sanabria, Sydney A. Barnes, Margaret E. Haerr, John C. Timmer
-
Patent number: 12331132Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, components of the multispecific polypeptides are connected by a non-cleavable linker. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: June 6, 2023Date of Patent: June 17, 2025Assignee: Inhibrx Biosciences, Inc.Inventors: Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, John C. Timmer
-
Publication number: 20250092137Abstract: The invention relates generally to multispecific polypeptides that bind at least CD3, a second antigen, and a receptor of a T cell, such as a costimulatory receptor or an inhibitory receptor, in which the multispecific polypeptide constructs are able to engage CD3. In some embodiments, the multispecific polypeptide constructs bind a costimulatory receptor and provide costimulatory binding activity. In some embodiments, the multispecific polypeptide constructs bind an inhibitory receptor and block inhibitory activity. In some aspects, the multispecific polypeptides have constrained CD3 binding and bind to or engage CD3 only upon binding to the second antigen, such as a tumor associated antigen. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, result in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: December 4, 2024Publication date: March 20, 2025Applicant: Inhibrx Biosciences, Inc.Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, Quinn DEVERAUX, Kyle S. JONES, Rajay A. PANDIT, John C. TIMMER
-
Patent number: 12195533Abstract: The invention relates generally to multispecific polypeptides that bind at least CD3, a second antigen, and a receptor of a T cell, such as a costimulatory receptor or an inhibitory receptor, in which the multispecific polypeptide constructs are able to engage CD3. In some embodiments, the multispecific polypeptide constructs bind a costimulatory receptor and provide costimulatory binding activity. In some embodiments, the multispecific polypeptide constructs bind an inhibitory receptor and block inhibitory activity. In some aspects, the multispecific polypeptides have constrained CD3 binding and bind to or engage CD3 only upon binding to the second antigen, such as a tumor associated antigen. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, result in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: July 23, 2019Date of Patent: January 14, 2025Assignee: Inhibrx Biosciences, Inc.Inventors: Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, Quinn Deveraux, Kyle S. Jones, Rajay A. Pandit, John C. Timmer
-
Publication number: 20240101704Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: November 27, 2023Publication date: March 28, 2024Applicant: Inhibrx, Inc.Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, Quinn DEVERAUX, John C. TIMMER
-
Patent number: 11866507Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: April 11, 2018Date of Patent: January 9, 2024Assignee: Inhibrx, Inc.Inventors: Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, Quinn Deveraux, John C. Timmer
-
Publication number: 20230348600Abstract: Provided herein are binding polypeptides that specifically bind CD28. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs that bind at least CD28. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors thereof, and methods of use and uses of the provided CD28 binding polypeptides for treating diseases and conditions, such as cancer.Type: ApplicationFiled: January 28, 2021Publication date: November 2, 2023Applicant: Inhibrx, Inc.Inventors: John C. TIMMER, Rutger H. JACKSON, Katelyn M. WILLIS, William S. CRAGO, Michael D. KAPLAN, Brendan P. ECKELMAN
-
Publication number: 20230295336Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, components of the multispecific polypeptides are connected by a non-cleavable linker. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: June 6, 2023Publication date: September 21, 2023Applicant: Inhibrx, Inc.Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, John C. TIMMER
-
Publication number: 20230124851Abstract: Provided herein are binding polypeptides that specifically bind B7H3. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind B7H3. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided B7H3 binding polypeptides for treating diseases and conditions, such as cancer.Type: ApplicationFiled: October 9, 2019Publication date: April 20, 2023Applicant: Inhibrx, lnc.Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, Kyle S. JONES, Angelica N. SANABRIA, Sydney A. BARNES, Margaret E. HAERR, John C. TIMMER
-
Publication number: 20210380679Abstract: Provided herein are binding polypeptides that specifically bind DLL3. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific contracts and chimeric antigen receptors, that bind DLL3. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided DLL3 binding polypeptides for treating diseases and conditions, such as cancer.Type: ApplicationFiled: October 9, 2019Publication date: December 9, 2021Applicant: Inhibrx, Inc.Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Kateiyn M. WILLIS, Raiay A. PANDIT, Angelica N. SANABRIA, Sydney A. BARNES, Margaret E. HAERR, John C. TIMMER
-
Publication number: 20210340273Abstract: Provided herein arm binding polypeptides that specifically bind 5T4. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind 5T4. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided 5T4 binding polypeptides for treating diseases and conditions, such as cancer.Type: ApplicationFiled: October 9, 2019Publication date: November 4, 2021Applicant: Inhlbrx, inc.Inventors: John C. TIMMER, Michael D. KAPLAN, Katelyn M. WILLIS, Raiay A. PANDIT, Angelica N. SANABRIA, Sydney A. BARNES, Margaret E. HAERR, Brendan P. ECKELMAN, Rutger H. JACKSON
-
Publication number: 20200048350Abstract: The invention relates generally to multispecific polypeptides that bind at least CD3, a second antigen, and a receptor of a T cell, such as a costimulatory receptor or an inhibitory receptor, in which the multispecific polypeptide constructs are able to engage CD3. In some embodiments, the multispecific polypeptide constructs bind a costimulatory receptor and provide costimulatory binding activity. In some embodiments, the multispecific polypeptide constructs bind an inhibitory receptor and block inhibitory activity. In some aspects, the multispecific polypeptides have constrained CD3 binding and bind to or engage CD3 only upon binding to the second antigen, such as a tumor associated antigen. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, result in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: July 23, 2019Publication date: February 13, 2020Applicant: Inhibrx, Inc.Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, Quinn DEVERAUX, Kyle S. JONES, Rajay A. PANDIT, John C. TIMMER
-
Publication number: 20190330366Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, components of the multispecific polypeptides are connected by a non-cleavable linker. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: April 10, 2019Publication date: October 31, 2019Applicant: Inhibrx, Inc.Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, John C. TIMMER
-
Publication number: 20190010242Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: April 11, 2018Publication date: January 10, 2019Applicant: Inhibrx, Inc.Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, Quinn Deveraux, John C. Timmer
-
Publication number: 20070282271Abstract: The device protects the proximal extension of an indwelling catheter and its percutaneous puncture site from moisture, fluids and risk of infection and maintains a clean environment and a fluid-impermeable and bacteria growth-inhibiting seal against the patient's skin when bathing, showering or swimming, and also protects others from being exposed to the patient's blood and catheter at that time. A faceplate is adhered to the skin about the catheter exit site with medical adhesive, the proximal end of the catheter is secured to the faceplate to prevent it from moving from within the patient's body, and a water-impermeable housing is sealed to the faceplate, with the proximal end of the catheter extending into a cavity of the housing. An antimicrobial material may be disposed on the backside of the faceplate. The device allows a patient to shower, bathe and swim while preventing the catheter from being dislodged from the patient.Type: ApplicationFiled: May 31, 2006Publication date: December 6, 2007Inventors: Michael D. Kaplan, Cornelius McCarthy, Steven M. Kaplan